Current Advances in ACE Inhibition: v.3

THE VASCULATURE: Hypertensive vascular disease - pathophysiological mechanisms; The role of angiotensin II and other growth factors in vascular hypertrophy; Vascular remodelling: a role for ACE inhibitors?. THE HEART: From hypertension to hypertrophy - molecular and cellular mechanisms; The renin-angiotensin system, the heart and the genesis of arrhythmias; What is the mechanism by which ACE inhibitors reduce mortality in heart failure?; Left ventrical structural remodelling - potential for therapeutic intervention; Is the ACE insertion/deletion polymorphism a risk factor for myocardial infarction? THE KIDNEY: Intrarenal actions of angiotensin II: role in health and disease; Inhibition of renin-angiotensin system and its effects on renal function - experimental evidence; Do ACE inhibitors preserve renal function in man?; The role of ACE inhibitors in patients with renal disease; Renovascular hypertension - the role of ACE inhibitors. CLINICAL PHARMACOLOGY: Differences between ACE inhibitors - are any of clinical relevance?; ACE inhibitors - concentration effect, dose response and duration of action in man; Indications for ACE inhibitors in the treatment of hypertension. OTHER INHIBITORS OF THE RENIN SYSTEM: Molecular and regulatory aspects of ACE - new developments; Localisation of angiotensin II receptors in various tissues; Differences between angiotensin II antagonists; Clinical evaluation of AII antagonists in hypertension; Renin inhibitors; Renin-angiotensin system inhibition: which intervention site should be targeted?. GENERAL: Diabetes - long-term renal protection - specific benefits from ACE inhibitors; Long-term renal protection - specific benefits from ACE inhibitors - the case for and against; Future use of ACE inhibitors.